Most treatments for multiple sclerosis (MS) don’t increase the risk of major problems when used during pregnancy, an analysis showed. “We found that most therapies were not associated with an increased risk of miscarriage, premature birth or major birth defects,” Kerstin Hellwig, MD, study co-author and MS specialist at…

About four in five adults with stable multiple sclerosis (MS) for at least five years remained free of disease activity after stopping first-line treatment with a disease-modifying therapy (DMT), according to a study based on data from the DOT-MS clinical trial. Still, disease activity reemerged in roughly 20%…

The rate of disability progression among people with relapsing-remitting multiple sclerosis (RRMS) has slowed over the years due to advances in disease-modifying therapies (DMTs), according to a long-term analysis. Patients diagnosed in recent decades have experienced fewer progression events associated with relapses, called relapse-associated worsening (RAW), and also…

People with primary progressive multiple sclerosis (PPMS) at younger ages are more likely to have higher disease activity, suggesting they may respond better to disease-modifying therapies, according to a review of published studies. “Our findings confirm that younger patients tend to have more inflammatory activity, and so younger…

People with multiple sclerosis (MS) who discontinue a disease-modifying treatment are more likely to have greater long-term disability than patients who continue with such therapies or go untreated, a registry database study reports. Findings also suggest that patients who self-report better mobility early in their disease course also…

Achieving NEDA — no evidence of disease activity — after two years of treatment was not common among people with relapsing-remitting multiple sclerosis (RRMS) at a center in Italy. NEDA more often was reached, however, when researchers didn’t include the first few months of treatment in their analysis, suggesting…

The rate of brain atrophy, or volume loss, may help in determining whether disease-modifying therapies (DMTs) are slowing disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a review of data from 12 published studies found. The analysis, “Brain Atrophy as an Outcome of Disease-Modifying Therapy for…

Children and adolescents with multiple sclerosis (MS) who receive high-efficacy disease-modifying therapies (DMTs) early on are significantly less likely to experience a relapse than those given a less efficacious drug, a real-world study found. While most patients on moderate-efficacy therapies eventually switched to a more effective one, a…

The use of disease-modifying therapies (DMTs) does not seem to affect sleep quality or daytime sleepiness in people with multiple sclerosis (MS), an Australian study finds. However, patients with a belief that DMT use impacted their sleep tended to have poorer sleep quality and report that the medication…

Note: This column describes the author’s own experiences with several disease-modifying therapies for multiple sclerosis. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Times, they’ve been a-changing for disease-modifying therapies (DMTs). When I was diagnosed with multiple…

Starting treatment with a high-efficacy disease-modifying therapy (DMT), rather than one with lesser efficacy, may reduce the number of times people with multiple sclerosis (MS) switch therapies due to a lack of effectiveness, a study of survey responses from doctors suggests. High-efficacy DMTs often are perceived to have…

Stem cell therapy is better than Gilenya (fingolimod) or Tysabri (natalizumab) at reducing relapse rates and easing disability for people with highly active relapsing-remitting multiple sclerosis (RRMS), a new analysis suggests. In contrast, findings suggest that the efficacy of stem cell therapy is not significantly different…

Disease relapses are no more likely in women with multiple sclerosis (MS) after fertility treatment than they were before such treatment, a study found. Researchers also observed that almost half of the women receiving fertility treatment were on disease-modifying MS therapies, which may have helped to keep a…

Note: This story was updated Oct. 31, 2022, to correct that in the six months after treatment discontinuation, relapses were reported in 18.8% of RMMS patients and 3.5% of those with SPMS. When multiple sclerosis (MS) patients stop their disease-modifying treatment, the risk of relapses and disease activity on…

The risk of transitioning from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) declined significantly after the introduction of disease-modifying therapies (DMT), according to a large nationwide Swedish study. Data showed that SPMS conversion risk rose by 3% each year before the first generation of…

Kesimpta (ofatumumab) is more cost-effective for treating relapsing-remitting multiple sclerosis (RRMS) than most other disease-modifying therapies (DMTs) approved in Canada, according to a new analysis. The analysis indicated that Kesimpta is generally more effective and associated with fewer costs than the majority of MS treatments, with the…

The likelihood of survival is about 7.5 times higher for people with multiple sclerosis (MS) who take their disease-modifying treatments as directed compared with those who do not, an analysis of data from U.S. veterans shows. The study, “Impact of Adherence with Disease-Modifying Therapies on All-Cause…

Tysabri (natalizumab) outperforms other disease-modifying therapies (DMTs) in its ability to lessen a range of patient-reported symptoms in people with multiple sclerosis (MS), according to data from a large real-world study. These symptoms include balance difficulties, sensory problems, feelings of anxiety, bladder problems, vision problems, and…

Delaying the start of disease-modifying therapies (DMTs) increases the risk of people with relapsing-remitting multiple sclerosis (RRMS) needing a disability pension to compensate for a permanent reduced capacity to work,  according to a Danish study. The study, “Time to first treatment and risk of disability pension…

Novartis’ Mayzent (siponimod) and Kesimpta (ofatumumab) are gaining ground among multiple sclerosis (MS) therapies in Canada, according to the latest Spherix Global Insights’ report. “Following an eventful 2021 that included the launch of two new brands — Novartis’ Kesimpta and BMS’ Zeposia — and generic versions of Biogen’s…

A measure of the nose’s sensitivity to smell could be used to detect whether treatments for relapsing multiple sclerosis (MS) are working or not, a new study indicates. The scientists noted that their results need to be validated through further study, but said the findings suggest that a smell…

A researcher at the University of Houston has received a $100,000 grant to investigate adherence to oral disease-modifying therapies (DMTs) among people with multiple sclerosis (MS), and correlations between adherence patterns and disease outcomes over time. The one-year grant from the Agency for Healthcare Research and Quality was awarded…

Patients’ underestimation of their own disease and the cost and side effects of disease-modifying therapies (DMTs) are among the main causes of delayed treatment initiation and non-adherence in multiple sclerosis (MS) patients, according to a report from OptimizeRx. These findings help uncover areas for improvement, which the health…

It’s been a decade since the opening of the UK MS Register, which sought to gain a better understanding of how multiple sclerosis (MS) affects patients’ everyday lives, with a goal, according to its website, toward fueling campaigns for “fair, relevant policy and improved health care.” Now, the…

High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on treatment, an analysis of placebo-controlled clinical trials shows. However, the therapy failed to improve other measures of disability, and was associated with inaccurate lab test results caused by high levels…

Exposure to multiple sclerosis (MS) disease-modifying therapies (DMTs), and particularly immunosuppressive DMTs, does not increase the risk of developing a severe form of COVID-19, or of dying from the disease, when adjusting for known risk factors, an Austrian registry-based study found. These findings add to data showing no…

Stem Cell Transplant Trial Enrolls First Patient in Minnesota It looks as if we’re moving closer to the day when stem cell transplants become an approved MS treatment in the U.S., at least I hope so. A trial is enrolling subjects to test the stem cells against several…

Nearly a third of people with multiple sclerosis (MS) who are younger than 40 are not being treated with disease-modifying treatments (DMTs), even though younger individuals are expected to get the most benefit from DMTs, according to a new study. “DMTs for MS are more frequently used at…

AstraZeneca’s COVID-19 vaccine appears to be reasonably safe for people with multiple sclerosis (MS), according to a small study of its use in the U.K. Vaccine side effects were in line with those experienced by the general population, its researchers said, such as flu-like symptoms and sore arms.

Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating multiple sclerosis (MS), showed strong launches in the country, according to the latest Spherix Global Insights’ report. However, due to several internal and external factors, sustained relevance of these…